Who are CG 5503;tapentadol's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Tramadol hydrochloride/ Acetaminophen, placebo and tramadol, Tramadol HCl/acetaminophen Extended Release, Tramadol hydrochloride/Acetaminophen Tab..

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cg-5503-tapentadol.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

CG 5503;tapentadol — Competitive Intelligence Brief

CG 5503;tapentadol (CG 5503;tapentadol) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic with norepinephrine reuptake inhibition. Area: Pain Management.

phase 3 Opioid analgesic with norepinephrine reuptake inhibition Mu-opioid receptor; norepinephrine transporter Pain Management Small molecule Live · refreshed every 30 min

Target snapshot

CG 5503;tapentadol (CG 5503;tapentadol) — Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Tapentadol is a mu-opioid receptor agonist and norepinephrine reuptake inhibitor that provides analgesia through dual mechanisms.

Comparator set (4 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
CG 5503;tapentadol TARGET	CG 5503;tapentadol	Johnson & Johnson Pharmaceutical Research & Development, L.L.C.	phase 3	Opioid analgesic with norepinephrine reuptake inhibition	Mu-opioid receptor; norepinephrine transporter
Tramadol hydrochloride/ Acetaminophen	Tramadol hydrochloride/ Acetaminophen	Janssen Korea, Ltd., Korea	marketed	Opioid analgesic combination	Mu-opioid receptor; norepinephrine transporter; serotonin transporter
placebo and tramadol	placebo and tramadol	University of Southern Denmark	marketed	Opioid analgesic with monoamine reuptake inhibition	Mu-opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol HCl/acetaminophen Extended Release	Tramadol HCl/acetaminophen Extended Release	Janssen Korea, Ltd., Korea	marketed	Opioid analgesic combination with NSAID alternative	Mu-opioid receptor; norepinephrine transporter; serotonin transporter
Tramadol hydrochloride/Acetaminophen Tab.	Tramadol hydrochloride/Acetaminophen Tab.	Daewon Pharmaceutical Co., Ltd.	phase 3	Opioid analgesic combination	Mu-opioid receptor; norepinephrine transporter; serotonin transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic with norepinephrine reuptake inhibition class)

Johnson & Johnson Pharmaceutical Research & Development, L.L.C. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). CG 5503;tapentadol — Competitive Intelligence Brief. https://druglandscape.com/ci/cg-5503-tapentadol. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab